AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
23 janv. 2025 08h50 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
22 janv. 2025 08h30 HE
|
AIM ImmunoTech Inc.
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
Most Americans Support Pandemic Policies but Have Concerns About Implementation
14 janv. 2025 09h53 HE
|
de Beaumont Foundation
Bethesda, Maryland, Jan. 14, 2025 (GLOBE NEWSWIRE) -- As the U.S. faces continuing infectious disease outbreaks, a new study shows that a majority of Americans are likely to support mitigation...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
14 janv. 2025 06h45 HE
|
BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
14 janv. 2025 06h45 HE
|
BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12 déc. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons
10 déc. 2024 10h02 HE
|
Association of American Physicians and Surgeons
Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
09 déc. 2024 04h00 HE
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06 déc. 2024 09h15 HE
|
AIM ImmunoTech Inc.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
15 nov. 2024 07h51 HE
|
InflaRx N.V.
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...